S&P 500 Technology Sector SEC Filings — June 10, 2026

10-06-2026

Oracle reported record Q4 FY2026 total revenues of $19.2B, up 21% YoY, driven by 47% growth in cloud revenues to $9.9B, with cloud infrastructure (IaaS) surging 93% to $5.8B. However, software revenues declined 2% to $6.8B as customers continue migrating from on-premise software to the cloud. Remaining Performance Obligations (RPO) reached a record $638B, up 363% YoY, largely from large-scale AI contracts. GAAP EPS rose 21% to $1.45, while non-GAAP EPS increased 24% to $2.111. For FY2026, total revenues were $67.4B (up 17%), but free cash flow was negative $23.7B due to heavy cloud infrastructure investments. The company guided Q1 FY2027 total revenue growth of 27%-29% and raised FY2027 non-GAAP EPS guidance to $8.05.

• · Q4 GAAP operating income was $6.1B (up 20%), non-GAAP operating income was a record $8.6B (up 22%).
• · Q4 GAAP net income available to common shareholders was $4.2B (up 23%), non-GAAP net income was $6.2B (up 26%).
• · FY2026 GAAP operating income was $20.6B (up 17%), non-GAAP operating income was a record $28.9B (up 16%).
• · FY2026 GAAP net income available to common shareholders was $17.0B (up 36%), non-GAAP net income was $22.2B (up 29%).
• · FY2026 operating cash flow was a record $32.0B (up 54%), but free cash flow was negative $23.7B due to cloud infrastructure investments.
• · RPO grew $85B sequentially from Q3 to Q4, reaching $638B.
• · Prepaid and customer-supplied hardware portions of large AI contracts total $75B, reducing Oracle's capital needs.
• · Oracle raised $43B in debt and $5B in equity in FY2026; expects ~$40B in debt/equity in FY2027 including $20B at-the-market equity issuance.
• · Oracle does not expect to issue additional debt in calendar year 2026.
• · Q1 FY2027 guidance: total revenue growth 27%-29%, cloud revenue growth 58%-64% USD, non-GAAP EPS $1.72-$1.76 USD.
• · FY2027 guidance: total revenue $90B (confirmed), non-GAAP EPS raised to $8.05 (18% growth adjusted).
• · Oracle Multicloud AI Database grew 404% in Q4.
• · Oracle Health expected to grow to double-digits in FY2027 with new AI patient care management system.
• · Quarterly dividend of $0.50 per share declared, payable July 24, 2026 to holders of record July 10, 2026.
• · Excluding one-time investment gains, Q4 non-GAAP EPS would be $2.03 (up 20% USD) and FY2026 non-GAAP EPS would be $6.83 (up 13% USD).

10-06-2026

Genco Shipping & Trading Limited (NYSE: GNK) filed a DEFA14A on June 10, 2026, urging shareholders to vote for all of its six highly qualified directors on the WHITE proxy card and to reject Diana Shipping Inc.'s inadequate $24.80 tender offer, which is below Genco's underlying net asset value (NAV) and provides no control premium. The filing highlights that all three proxy advisory firms (ISS, Glass Lewis, Egan-Jones) recommend voting for Genco's directors, while Diana's nominees are criticized for ties to value destruction and lack of independence. Genco's Board emphasizes its Comprehensive Value Strategy has delivered large and growing dividends and superior returns, but the filing does not provide specific financial metrics or period-over-period comparisons.

• · Genco's fleet consists of 43 vessels with an average age of 12.6 years and aggregate capacity of approximately 4,935,000 dwt.
• · Diana initially nominated four additional nominees but withdrew them after proxy advisory firms recommended Genco's directors.
• · Jens Ismar led Western Bulk into bankruptcy as CEO; Paul Cornell received a withhold recommendation from ISS for his service on Excel Maritime's board.
• · Genco's Board recommends continuation of the shareholder rights plan to prevent a creeping takeover by Diana.
• · The filing does not provide any financial results, dividend amounts, or period-over-period comparisons.

10-06-2026

QumulusAI filed an S-1/A registration statement with the SEC on June 10, 2026, detailing its governance structure and executive compensation for the years ended December 31, 2025 and 2024. The filing reveals changes in executive leadership, including the appointment of Michael Maniscalco as CEO effective September 1, 2025, and provides compensation data showing total 2025 pay for named executive officers ranging from $75,033 (Patrick Gahan) to $392,750 (Scott Krosnowski). While new executive compensation packages include substantial equity incentives tied to Nasdaq listing and performance milestones, the filing shows significant year-over-year declines in total compensation for former CEO Robert Bissell ($218,000 in 2025 vs $245,500 in 2024), reflecting his resignation.

• · The filing is an S-1/A registration statement (No. 333-292514) filed on June 10, 2026.
• · Compensation committee and nominating and corporate governance committee are fully independent under Nasdaq rules.
• · QumulusAI is an 'emerging growth company' under SEC rules.
• · Houston Aderhold's 2024 salary included $50,000 paid via consulting agreement with MHA Technologies Inc., similar to Mr. Bissell's arrangement with Chalin Inc.
• · Mr. Krosnowski served part-time through January 15, 2025, before moving to full-time.
• · Mr. Chatterjee's employment began after the acquisition of TCM.
• · No 401(k) matching contributions were made for named executive officers in 2024.
• · Mr. Maniscalco's base salary automatically increases to $350,000 once listed on Nasdaq and to $400,000 six months after listing if the company achieves $2 billion market cap.
• · Mr. Maniscalco's annual bonus minimum is $100,000.
• · Mr. Maniscalco's annual RSU grants will be at least $500,000 ($750,000 if mid-cap).
• · Special RSU grants for Gahan ($975,810) and Krosnowski ($610,092) vest in full on September 1, 2026, tied to direct listing work.
• · Four named executive officers (Gahan, Maniscalco, Krosnowski, Chatterjee) had no compensation data for 2024 as they were not NEOs that year.

10-06-2026

Aditxt, Inc. (NASDAQ: ADTX) announced a definitive business combination agreement valuing its 100%-owned subsidiary Ignite Proteomics at an implied equity value of approximately $150 million. Upon closing, Ignite is expected to separate from Aditxt and become an independent NYSE-listed public company through a newly formed holding company (Pubco), while Aditxt continues as a separate Nasdaq-listed company. The transaction is subject to customary closing conditions, including shareholder approvals and SEC registration, and is intended to unlock value for Aditxt while providing Ignite with dedicated capital and visibility to advance its functional proteomics platform in precision oncology.

• · Ignite's current commercial focus is in breast cancer, with a broader development strategy intended to support expansion into additional tumor types and treatment settings.
• · Net proceeds from the transaction are expected to support Ignite's commercialization initiatives, clinical evidence generation, working capital needs and general corporate purposes.
• · Following closing, the combined company is expected to be led by Ignite's management team.
• · The acquisition corp. is a special purpose acquisition company (SPAC) whose identity is not disclosed in the press release.
• · Aditxt acquired Ignite as part of its strategy to identify, acquire and advance differentiated health innovation platforms.

10-06-2026

Apple Hospitality REIT, Inc. announced that Elizabeth S. Perkins, Senior Vice President and Chief Financial Officer, has been appointed as the Company's principal accounting officer effective June 10, 2026, succeeding Rachel Labrecque, who passed away on June 9, 2026.

• · Ms. Perkins assumed the additional role of principal accounting officer on June 10, 2026.
• · Ms. Labrecque's passing occurred on June 9, 2026.
• · Ms. Perkins' biographical information is incorporated by reference from the Company's definitive proxy statement filed on April 2, 2026.

10-06-2026

AIM ImmunoTech Inc. amended its Bylaws effective June 9, 2026, primarily to revise Section 1.9 regarding stockholder voting. The amendment establishes a majority-of-votes-cast standard for approving proposals (excluding abstentions and broker non-votes) and retains a plurality standard for director elections. The change aligns voting procedures with common corporate governance practices but does not materially alter the company's financial position or operations.

10-06-2026

ImmunityBio held its 2026 Annual Meeting on June 9, 2026, with 85% of outstanding shares represented. All nine director nominees were re-elected, and the appointment of Deloitte & Touche as auditor was ratified. The meeting had high shareholder turnout and strong support for management proposals.

• · All nine director nominees received over 97% of votes cast (excluding broker non-votes).
• · Ratification of Deloitte & Touche received 882,420,139 votes for, 1,675,960 against, and 1,070,960 abstentions.
• · Broker non-votes were 151,521,174 for each director election and none for auditor ratification.

10-06-2026

J.P. Morgan Chase Commercial Mortgage Securities Corp. issued $648,862,000 in public certificates and private certificates for the JPMF1 Multifamily Mortgage Trust 2026-FX1, backed by 17 multifamily mortgage loans. The net proceeds to the registrant were approximately $656,510,249 after expenses of $6,367,170. The retaining sponsor satisfied its credit risk retention obligation by purchasing risk retention certificates with an aggregate fair value of approximately $37,379,615, representing 5.08% of the aggregate fair value of all certificates (excluding Class R), exceeding the required 5.00% threshold.

• · The registration statement (file no. 333-280318) was originally declared effective on September 9, 2024.
• · The public certificates were sold to underwriters including J.P. Morgan Securities LLC, ATLAS SP Securities, Goldman Sachs & Co. LLC, and Santander US Capital Markets LLC.
• · The private certificates (excluding risk retention certificates) were sold to the same four firms as initial purchasers in a transaction exempt from registration under Section 4(a)(2) of the Securities Act.
• · The risk retention certificates were sold to MF1 REIT III FR Retention Holder LLC, a majority-owned affiliate of MF1.
• · Legal and tax opinions were rendered by Cadwalader, Wickersham & Taft LLP and are attached as exhibits.
• · There are no material differences between the valuation methodology and key inputs used in the preliminary prospectus and those used at closing.

10-06-2026

ImmuCell Corporation (ICCC) announced a manufacturing capacity expansion program authorized by its Board of Directors on June 4, 2026. The first phase, costing ~$3.5 million and lasting ~12 months, involves renovating a former Re-Tain® facility and adding a new freeze dryer to expand drying capacity. A second phase will repurpose Re-Tain® equipment and add automation to replace and expand First Defense® colostrum processing capacity, though costs and timelines are not provided. The strategy follows a late 2025/early 2026 decision to suspend in-house manufacturing of Re-Tain® and instead focus on expanding First Defense® production, but no financial performance data or growth metrics are disclosed to assess expected outcomes.

• · The second phase will involve additional unquantified investments, including detailed engineering work to develop an efficient and scalable process.
• · The capacity expansion follows the December 2025/January 2026 decision to suspend in-house Re-Tain® manufacturing and convert facilities for First Defense® production.
• · No current or prior period production volumes, revenue figures, or demand growth rates are provided in this filing.

10-06-2026

Dakota Community Bank & Trust NA filed its 13F-HR for the quarter ending March 31, 2026, reporting a portfolio value of approximately $295.6 million across 96 holdings. The largest positions include Tesla (12,235 shares, $4.55M), Microsoft (3,139 shares, $1.16M), and Nvidia (6,304 shares, $1.10M). The filing shows a concentrated equity portfolio with significant exposure to large-cap technology and energy stocks, but no prior quarter comparison is available to assess performance trends.

• · The portfolio includes a leveraged ETF position: Direxion Daily TSLA Bull 2X Shares (23,297 shares, $283,059).
• · Tesla is the largest single stock position by value at $4.55M (12,235 shares), with a significant portion (11,601 shares) held in the Direxion leveraged ETF.
• · The bank holds 96 positions with a total market value of $295.6M as of March 31, 2026.
• · No prior quarter comparison data is available in this filing to assess changes in holdings.
• · The portfolio is diversified across sectors including technology, energy, financials, healthcare, and consumer goods.

10-06-2026

BlockchAIn Digital Infrastructure, Inc. (AIB) announced the pricing of a $55 million underwritten public offering of 33,333,334 shares at $1.65 per share, with net proceeds intended for working capital, capital expenditures, and general corporate purposes. The offering is expected to close on June 8, 2026, and includes a 45-day underwriter option for up to an additional 4,999,999 shares. No negative or flat performance metrics are reported in this filing.

• · The offering is underwritten by Lucid Capital Markets as sole book-running manager.
• · The registration statement (Form S-1, File No. 333-296413) was declared effective by the SEC on June 4, 2026.
• · The underwriter has a 45-day option to purchase up to an additional 4,999,999 shares at the public offering price less discounts.
• · Net proceeds will be used for working capital, capital expenditures, and general corporate purposes.
• · The offering is expected to close on or about June 8, 2026.

10-06-2026

Weave Communications held its 2026 Annual Meeting on June 10, 2026, where shareholders elected two Class I directors (George Scanlon and Debra Tomlin) and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Both director nominees received majority support, though a significant number of votes were withheld (over 15 million each), and the auditor ratification passed overwhelmingly with 63,358,833 votes in favor.

• · The annual meeting was held on June 10, 2026.
• · Both director nominees were elected based on the Board's recommendation.
• · There were no broker non-votes on the auditor ratification proposal.
• · The auditor ratification had only 12,382 votes against and 16,200 abstentions.